The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ

Alaeikhanehshir S, Schmitz RSJM, van den Belt-Dusebout AW et al (2023) The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-023-07168-8 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478–488 Allred DC, Bryant J, Land S et al (2022) Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from the NSABP protocol B-24 [abstract]. Breast Cancer Res Treat 76(Suppl 1):A30 Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A et al (2023) Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol 41(17):3116–3121 Forbes JF, Sestak I, Howell A et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387(10021):866–873 Margolese RG, Cecchini RS, Julian TB et al (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):849–856 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 17 Nov 2023